News & Events
Press Releases
Berkeley, CA, March 8, 2021 – Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, announced today that Rachel Haurwitz, Ph.D., Caribou’s President and Chief Executive Officer, will present a company overview at upcoming investor conferences in March.
Berkeley, CA, March 3, 2021 – Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, announced today the successful completion of an oversubscribed $115 million Series C financing. Proceeds from the financing will be used to further develop the Company’s proprietary, next-generation CRISPR technology platform and to advance the Company’s pipeline of wholly-owned allogeneic immune cell therapies for oncology with best-in-class potential.
In the News
CRISPR treating cancer, Rachel Haurwitz, Co-founder and CEO, Caribou Biosciences
“Rachel is a co-founder of Caribou Biosciences and has been President and CEO since its inception in 2011. Rachel is an inventor on several patents and patent applications covering multiple CRISPR-based technologies, and has co-authored scientific papers in high impact journals characterizing CRISPR-Cas systems.”
Caribou and AbbVie Initiate Development Partnership for CAR T-Cell Products
“AbbVie and Caribou Biosciences, Inc have announced that the companies have entered into a collaboration and license agreement for the research and development of chimeric antigen receptor (CAR) T-cell therapeutics.”